

Nicolas Roberto Robles

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9567584/publications.pdf>

Version: 2024-02-01

122
papers

978
citations

623734

14
h-index

610901

24
g-index

146
all docs

146
docs citations

146
times ranked

1311
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome. <i>Atherosclerosis</i> , 2010, 209, 300-305.	0.8	55
2	Renin-“Angiotensin System Blocking Drugs. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 14-33.	2.0	53
3	Non-Proteinuric Diabetic Nephropathy. <i>Journal of Clinical Medicine</i> , 2015, 4, 1761-1773.	2.4	49
4	Prevalence of obesity and associated cardiovascular risk: the DARIOS study. <i>BMC Public Health</i> , 2013, 13, 542.	2.9	48
5	The European/International Fibromuscular Dysplasia Registry and Initiative (FEIRI)“clinical phenotypes and their predictors based on a cohort of 1000 patients. <i>Cardiovascular Research</i> , 2021, 117, 950-959.	3.8	33
6	Hypertension in the Elderly. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2015, 12, 136-145.	1.0	30
7	The value of a formula including haematocrit, blood urea and gender (HUGE) as a screening test for chronic renal insufficiency. <i>Journal of Nutrition, Health and Aging</i> , 2011, 15, 480-484.	3.3	28
8	Comparative Effects of Fosinopril and Irbesartan on Hematopoiesis in Essential Hypertensives. <i>Renal Failure</i> , 2004, 26, 399-404.	2.1	24
9	Lercanidipine in the management of hypertension: An update. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2017, 8, 155.	0.4	24
10	Treatment of Proteinuria with Lercanidipine Associated with Renin-Angiotensin Axis-Blocking Drugs. <i>Renal Failure</i> , 2010, 32, 192-197.	2.1	22
11	Dihydropyridine calcium channel blockers and renal disease. <i>Hypertension Research</i> , 2017, 40, 21-28.	2.7	16
12	Hemodialysis With Cuprophane or Polysulfone: Effects on Uremic Polyneuropathy. <i>American Journal of Kidney Diseases</i> , 1993, 21, 282-287.	1.9	15
13	Correlation of Serum Magnesium and Serum Lipid Levels in Hemodialysis Patients. <i>Nephron</i> , 1998, 78, 118-119.	1.8	15
14	Cystatin c and blood pressure: Results of 24h ambulatory blood pressure monitoring. <i>European Journal of Internal Medicine</i> , 2010, 21, 185-190.	2.2	14
15	Blood Pressure in Renal Disease: How to Accomplish the Goal?. <i>Cardiovascular Therapeutics</i> , 2012, 30, 193-198.	2.5	14
16	Non-proteinuric diabetic nephropathy is the main cause of chronic kidney disease: Results of a general population survey in Spain. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2017, 11, S777-S781.	3.6	14
17	Risk factors for non-diabetic renal disease in diabetic patients. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 380-388.	2.9	14
18	The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease. <i>Clinical Drug Investigation</i> , 2016, 36, 421-431.	2.2	13

#	ARTICLE	IF	CITATIONS
19	Does a blood pressure J curve exist for patients with chronic kidney disease?. Journal of Clinical Hypertension, 2017, 19, 764-770.	2.0	13
20	Association between serum uric acid and carotid disease in patients with atherosclerotic acute ischemic stroke. Vascular, 2019, 27, 19-26.	0.9	13
21	Cross-sectional survey of the prevalence of reduced estimated glomerular filtration rate, albuminuria and cardiovascular risk in a native Spanish population. Journal of Nephrology, 2013, 26, 675-682.	2.0	13
22	Calcium Antagonists and Renal Failure Progression. Renal Failure, 2008, 30, 247-255.	2.1	12
23	Prevalence of abnormal urinary albumin excretion in a population-based study in Spain: results from the HERMEX Study. European Journal of Clinical Investigation, 2012, 42, 1272-1277.	3.4	12
24	Hematocrit, urea and gender: The Hematocrit, Urea and Gender formula for prognosing progressive renal failure in diabetic nephropathy. European Journal of Internal Medicine, 2012, 23, 283-286.	2.2	12
25	Prevalence of abnormal urinary albumin excretion in elderly people: a Spanish survey. International Urology and Nephrology, 2013, 45, 553-560.	1.4	12
26	Prevalencia del hiperparatiroidismo secundario en pacientes con enfermedad renal crónica estadios 3 y 4 atendidos en medicina interna. Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion, 2015, 62, 300-305.	0.8	11
27	Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trial. Orphanet Journal of Rare Diseases, 2016, 11, 128.	2.7	11
28	Potential beneficial effects of sacubitril-valsartan in renal disease: a new field for a new drug. Expert Opinion on Investigational Drugs, 2017, 26, 651-659.	4.1	11
29	Lack of transmission of hepatitis C virus in a haemodialysis unit. Nephrology Dialysis Transplantation, 1992, 7, 981-982.	0.7	10
30	1997 Spanish Nephrology Association (Sociedad Española de Nefrología) Report on Dialysis and Transplantation. Nephrology Dialysis Transplantation, 1999, 14, 2841-2845.	0.7	10
31	Symmetrical ambulatory arterial stiffness index: Relationship with microalbuminuria and renal function. European Journal of Internal Medicine, 2010, 21, 118-122.	2.2	10
32	The H.U.G.E. formula (hematocrit, urea, sex) for screening chronic kidney disease (CKD) in an age-stratified general population. Journal of Nutrition, Health and Aging, 2015, 19, 688-692.	3.3	10
33	Lercanidipine valuable effect on urine protein losses: the RED LEVEL study. Current Medical Research and Opinion, 2016, 32, 29-34.	1.9	10
34	Iron deficiency in chronic kidney disease patients with diabetes mellitus. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2018, 12, 933-937.	3.6	10
35	End-stage renal failure due to diabetic nephropathy in Spain. Nephrology Dialysis Transplantation, 1996, 11, 393-394.	0.7	9
36	Sympathetic Skin Response in Hemodialysis Patients: Correlation with Nerve Conduction Studies and Adequacy of Dialysis. Nephron, 1999, 82, 12-16.	1.8	9

#	ARTICLE	IF	CITATIONS
37	Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients. <i>International Journal of Clinical Practice</i> , 2005, 59, 478-484.	1.7	9
38	Hyperhomocysteinemia in patients with mild chronic renal failure. <i>European Journal of Internal Medicine</i> , 2005, 16, 334-338.	2.2	9
39	Use of Î±1-microglobulin for diagnosing chronic interstitial nephropathy. <i>Clinical and Experimental Medicine</i> , 2014, 14, 315-320.	3.6	9
40	Serum uric acid levels and outcome during admission in acute ischaemic stroke, depending on renal function. <i>International Journal of Neuroscience</i> , 2018, 128, 906-912.	1.6	9
41	Untoward effects of chronic dual renin-angiotensin system blockade: influence of previous chronic renal failure. <i>International Journal of Clinical Practice</i> , 2006, 60, 1035-1039.	1.7	8
42	Persistent microalbuminuria after treatment with renin-angiotensin axis blockers: causes and results of treatment intensification. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2011, 12, 333-339.	1.7	8
43	Características clínicas y mortalidad de la insuficiencia cardiaca. Estudio INCAex. <i>Revista Clínica Española</i> , 2013, 213, 16-24.	0.6	8
44	Prevalence of secondary hyperparathyroidism in patients with stage 3 and 4 chronic kidney disease seen in internal medicine. <i>Endocrinología Y Nutrición (English Edition)</i> , 2015, 62, 300-305.	0.5	8
45	Sacubitril-Valsartan Improves Anemia of Cardiorenal Syndrome (CRS). <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2021, 19, 93-97.	1.0	8
46	Genetics Variants in the Epoxygenase Pathway of Arachidonic Metabolism Are Associated with Eicosanoids Levels and the Risk of Diabetic Nephropathy. <i>Journal of Clinical Medicine</i> , 2021, 10, 3980.	2.4	7
47	Alfa-1-microglobulina: valor pronóstico en la enfermedad renal crónica. <i>Medicina Clínica</i> , 2021, 157, 368-370.	0.6	7
48	Effectiveness of eprosartan in diabetic hypertensive patients. <i>European Journal of Internal Medicine</i> , 2008, 19, 27-31.	2.2	6
49	Symmetrical Ambulatory Arterial Stiffness Index: Relationship with Serum Cystatin C Levels. <i>Renal Failure</i> , 2011, 33, 255-260.	2.1	6
50	Increased frequency of microalbuminuria in patients receiving statins. <i>Clinical Lipidology</i> , 2013, 8, 257-262.	0.4	6
51	Secondary hyperparathyroidism prevalence and profile, between diabetic and non-diabetic patients with stage 3 to 4 chronic kidney disease attended in internal medicine wards. MiPTH study. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2016, 10, S16-S21.	3.6	6
52	PAIT-survey: Prevalence of albuminuria in patients with diabetes and hypertension in Turkey. <i>Primary Care Diabetes</i> , 2018, 12, 558-564.	1.8	6
53	Proton pump inhibitors and risk for recurrent ischemic events or death in outpatients with symptomatic artery disease. <i>Atherosclerosis</i> , 2020, 292, 84-89.	0.8	6
54	Systolic Blood Pressure and Outcomes in Stable Outpatients with Recent Symptomatic Artery Disease: A Population-Based Longitudinal Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 9348.	2.6	6

#	ARTICLE	IF	CITATIONS
55	Nighttime Blood Pressure Fall in Renal Disease Patients. <i>Renal Failure</i> , 2003, 25, 829-837.	2.1	5
56	Sympathetic Skin Response in Peritoneal Dialysis Patients. <i>ASAIO Journal</i> , 2003, 49, 88-91.	1.6	5
57	Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2009, 10, 195-200.	1.7	5
58	Hidden chronic renal insufficiency and cardiovascular events in patients with hypertension in a primary care center. <i>Renal Failure</i> , 2010, 32, 757-765.	2.1	5
59	J-shaped curve for cardiovascular mortality: systolic or diastolic blood pressure?. <i>Journal of Nephrology</i> , 2019, 32, 347-353.	2.0	5
60	Does established vascular kidney disease exist?. <i>Journal of Clinical Hypertension</i> , 2020, 22, 296-298.	2.0	5
61	Hypertension in Kidney Transplant Recipients: Where Are We Today?. <i>Current Hypertension Reports</i> , 2021, 23, 21.	3.5	5
62	The HUGE formula (hematocrit, urea and gender): association with cardiovascular risk. <i>European Review for Medical and Pharmacological Sciences</i> , 2013, 17, 1889-93.	0.7	5
63	Do we need glomerular filtration rate calculation?. <i>International Journal of Clinical Practice</i> , 2007, 61, 1611-1613.	1.7	4
64	Estimated Glomerular Filtration Rate from Serum Cystatin C: Significant Differences among Several Equations Results. <i>Renal Failure</i> , 2012, 34, 871-875.	2.1	4
65	Recomendaciones de manejo de la afectación renal en el complejo esclerosis tuberosa. <i>Nefrología</i> , 2020, 40, 142-151.	0.4	4
66	PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 43-49.	2.2	4
67	Genetic Variants in PGE2 Receptors Modulate the Risk of Nephrosclerosis and Clinical Outcomes in These Patients. <i>Journal of Personalized Medicine</i> , 2021, 11, 772.	2.5	4
68	Membranous Glomerulonephritis after Kidney Transplantation and Urologic Complications. <i>American Journal of Nephrology</i> , 1992, 12, 279-280.	3.1	3
69	ACUTE EFFECT OF HEMODIALYSIS WITH POLYACRYLONITRILE MEMBRANE ON NERVE CONDUCTION VELOCITIES. <i>Renal Failure</i> , 2001, 23, 251-257.	2.1	3
70	Polymorphisms in vasoactive eicosanoid genes of kidney donors affect biopsy scores and clinical outcomes in renal transplantation. <i>PLoS ONE</i> , 2019, 14, e0224129.	2.5	3
71	Prognostic Role of Hyponatremia in Heart Failure Patients Depending on Renal Disease: Clinical Evidence. <i>Cardiology</i> , 2019, 144, 1-8.	1.4	3
72	Alpha-1-microglobulin: Prognostic value in chronic kidney disease. <i>Medicina Clínica (English Edition)</i> , 2021, 157, 368-370.	0.2	3

#	ARTICLE	IF	CITATIONS
73	Plasma and urinary concentrations of arachidonic acid-derived eicosanoids are associated with diabetic kidney disease. EXCLI Journal, 2021, 20, 698-708.	0.7	3
74	Tag-SNPs in Phospholipase-Related Genes Modify the Susceptibility to Nephrosclerosis and its Associated Cardiovascular Risk. Frontiers in Pharmacology, 2022, 13, 817020.	3.5	3
75	Dual renin-angiotensin system blockade: In patients with single functioning kidney and proteinuria. European Journal of Internal Medicine, 2009, 20, 186-189.	2.2	2
76	Long-Term Antiproteinuric Effect of Dual Renin-Angiotensin System Blockade. Cardiovascular Therapeutics, 2009, 27, 101-107.	2.5	2
77	Erythropoiesis stimulating agents (ESAs) for congestive heart failure: The red and the black. European Journal of Internal Medicine, 2014, 25, 193-196.	2.2	2
78	Anemia as very late-onset cytomegalovirus disease after kidney transplantation. Transplant Infectious Disease, 2018, 20, e12797.	1.7	2
79	Recommendations for the management of renal involvement in tuberous sclerosis complex. Nefrologia, 2020, 40, 142-151.	0.4	2
80	Cardiovascular risk assessment after one-year acute ischemic stroke based on uric acid levels and renal dysfunction. A clinical study. International Journal of Neuroscience, 2021, 131, 609-614.	1.6	2
81	ACUTE EFFECT OF HEMODIALYSIS ON SYMPATHETIC SKIN RESPONSE. Renal Failure, 2001, 23, 843-850.	2.1	1
82	Cardiovascular Risk in Uremic Patients: Darkness after AURORA. Renal Failure, 2010, 32, 269-272.	2.1	1
83	Edema agudo de pulmón no cardiogénico por hidroclorotiazida. Hipertension Y Riesgo Vascular, 2010, 27, 128-129.	0.6	1
84	Research update for articles published in EJCI in 2012. European Journal of Clinical Investigation, 2014, 44, 1010-1023.	3.4	1
85	PP.32.08. Journal of Hypertension, 2015, 33, e422.	0.5	1
86	A comparison of cystatin C concentrations between patients with chronic interstitial nephritis and glomerular diseases. Journal of Clinical Laboratory Analysis, 2018, 32, .	2.1	1
87	Lack of Correlation of Carotid Intima-Media Index and Peripheral Artery Disease. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 379-383.	2.2	1
88	¿Dosis máximas de bloqueantes del eje renina-angiotensina en nefropatía diabética?. Medicina Clínica, 2021, 157, 20-21.	0.6	1
89	Perfil clínico de los pacientes tratados con evolocumab en unidades hospitalarias de nefrología en España (RETOSS-NEFRO). Nefrologia, 2022, 42, 301-310.	0.4	1
90	KDIGO guidelines for the management of blood pressure in chronic kidney disease: A sprint to the curve. European Journal of Internal Medicine, 2021, 93, 21-23.	2.2	1

#	ARTICLE	IF	CITATIONS
91	Pitavastatin: Coronary Atherosclerotic Plaques Changes and Cardiovascular Prevention. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 137-144.	2.2	1
92	N.R. Robles. Medicina Clínica, 2000, 114, 679.	0.6	0
93	Lercanidipine in chronic renal failure (CRF). American Journal of Hypertension, 2003, 16, A99-A100.	2.0	0
94	Fixed-Dose Combination Lercanidipine/Enalapril. Drugs, 2007, 67, 107-108.	10.9	0
95	Dual renin-angiotensin system blockade: on the target. International Journal of Clinical Practice, 2008, 62, 1134-1136.	1.7	0
96	Limitaciones de la automedicación de la presión arterial. Hipertension, 2008, 25, 81-82.	0.0	0
97	Glomerular filtration rate estimated from serum cystatin. International Journal of Clinical Practice, 2011, 65, 1108-1109.	1.7	0
98	A proposal for improving the KDIGO renal disease risk table. International Urology and Nephrology, 2012, 44, 1431-1433.	1.4	0
99	Intensive treatment of persistent microalbuminuria: determinants of treatment resistance. Open Medicine (Poland), 2013, 8, 302-309.	1.3	0
100	Cystatin C as a mortality predictor in a hypertensive population in Extremadura, Spain. Medicina Clínica (English Edition), 2015, 145, 198-200.	0.2	0
101	SP468DIABETES MELLITUS AND RENAL DISEASE: RESULTS OF A GENERAL POPULATION SURVEY IN SPAIN. Nephrology Dialysis Transplantation, 2015, 30, iii535-iii535.	0.7	0
102	Atherosclerotic ischemic renal disease: Clinical challenges. Medicina Clínica (English Edition), 2015, 144, 163-165.	0.2	0
103	Erythropoietin, chronic renal failure and cancer. Medicina Clínica (English Edition), 2016, 146, 539-540.	0.2	0
104	MPO39THE EFFECT OF EVEROLIMUS IN PATIENTS WITH RENAL ANGIOMYOLIPOMA ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX. Nephrology Dialysis Transplantation, 2016, 31, i355-i356.	0.7	0
105	Afectación glomerular en paciente con enfermedad falciforme. Nefrología, 2017, 37, 437-439.	0.4	0
106	Glomerular involvement in patient with sickle cell disease. Nefrología, 2017, 37, 437-439.	0.4	0
107	[PP.07.12] HEMATOCRIT UREA AND GENDER (H.U.G.E.) FORMULA AND THE CKD PROGNOSIS CONSORTIUM EQUATION. Journal of Hypertension, 2017, 35, e140.	0.5	0
108	SP416DIABETIC PATIENTS WITH DIABETIC NEPHROPATHY HAVE WORSE RENAL PROGNOSIS. STUDY BIODIAB-GLOSEN-GEENDIAB. Nephrology Dialysis Transplantation, 2018, 33, i487-i487.	0.7	0

#	ARTICLE	IF	CITATIONS
109	SP425RENAL BIOPSY IN DIABETIC PATIENTS: PRELIMINARY RESULTS OF THE SPANISH MULTICENTER STUDY BIODIAB-GLOSEN-GEENDIAB. Nephrology Dialysis Transplantation, 2018, 33, i491-i491.	0.7	0
110	SP306A PROSPECTIVE STUDY OF THE EFFECT OF CHRONIC KIDNEY DISEASE ON THE INCIDENCE OF CARDIOVASCULAR EVENTS IN A NATIVE SPANISH POPULATION. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
111	Automated blood pressure measurement in consultation. Medicina Clínica (English Edition), 2020, 154, 59-60.	0.2	0
112	Nuevos aspectos en la vigilancia epidemiológica con relación a las enfermedades virales en hemodiálisis. Nefrología, 2020, 40, 570-571.	0.4	0
113	New aspects in epidemiological surveillance in relation to viral diseases in haemodialysis. Nefrología, 2020, 40, 570-571.	0.4	0
114	Efecto de la enfermedad renal crónica sobre la incidencia de episodios cardiovasculares en población española. Medicina Clínica, 2021, 157, 569-574.	0.6	0
115	Validation of the QMon-20 oscillometric blood pressure monitor for professional office use in the general population according to the ANSI/ESH/ISO 81060â€“2:2018 protocol. Blood Pressure Monitoring, 2021, 26, 393-395.	0.8	0
116	Maximum doses of renin-angiotensin axis blockers in diabetic nephropathy?. Medicina Clínica (English) Tj ETQq0 0,0 rgBT /Overlock 10	0.2	0
117	Antiretroviral Treatment and Antihypertensive Therapy. Current Pharmaceutical Design, 2021, 27, 4116-4124.	1.9	0
118	Efecto del cambio en el peso tras el trasplante renal en la supervivencia del injerto. Nefrología, 2021, , .	0.4	0
119	Pitavastatin: Similarities and Differences Compared With Other Statins. ACTA Pharmaceutica Scientia, 2021, 59, 655-669.	0.2	0
120	Medición automatizada de presión arterial en consulta. Medicina Clínica, 2020, 154, 59-60.	0.6	0
121	Study of the effect of chronic kidney disease on the incidence of cardiovascular events in a native Spanish population. Medicina Clínica (English Edition), 2021, , .	0.2	0
122	Historical Archive of Blood Pressure and Evolution of Hypertension. Journal of Drug Delivery and Therapeutics, 2022, 12, 215-219.	0.5	0